STERIALS

A biopharmaceutical company focused on discovering and developing "True Human" monoclonal antibodies for the treatment of a wide range of diseases. These naturally derived monoclonal antibodies are expected to be safer, more effective and have shorter development times than their synthetic counterparts, and the company is advancing the development of product candidates targeting inflammatory and infectious diseases.